Universal Flu Vaccine Candidate: Osivax Enters Agreement with NIH to test
by Press Release from Outbreak News Today on (#4W5ZN)
Osivax announced Thursday that it has entered into an agreement with the United States' National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to further advance the development of its lead universal flu vaccine candidate, OVX836. The Company's proprietary oligoDOM(R) technology enables OVX836 to target the NucleoProtein, a ["]
The post Universal Flu Vaccine Candidate: Osivax Enters Agreement with NIH to test appeared first on Outbreak News Today.